Loading...
NPI 1407180847 · Sandwich, MA · Mobile Radiology Clinic/Center
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Cape Cod Pet/ct Services LLC is a mobile radiology clinic/center provider located in Sandwich, Massachusetts. This profile covers 4 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Cape Cod Pet/ct Services LLC |
| Address | 2 Jan Sebastian Dr |
| City | Sandwich |
| State | MA |
| ZIP | 02563 |
| Taxonomy | Mobile Radiology Clinic/Center |
| NPI Enumerated | October 1, 2009 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $445.1K |
The provider is functionally a PET/CT-focused mobile radiology clinic: its top billed services are PET/CT imaging (78815, 78816) and radiopharmaceutical diagnostics (A9595, A9552), which matches the Mobile Radiology Clinic/Center taxonomy and the code descriptions for fused PET/CT studies and multiple tracer types. Medicare revenue of $2.1M and Medicaid revenue of $445.1K are concentrated in PET imaging and tracer supply rather than a broader mix of imaging modalities or ancillary services.
Medicare revenue is highly concentrated: the top three Medicare codes account for 93.5% of total Medicare revenue, with 78815 contributing $1.1M (50.1% of Medicare revenue), A9595 contributing $602.4K (28.3%), and A9552 contributing $321.3K (15.1%). This concentration indicates the practice’s Medicare business is driven almost exclusively by high-volume PET/CT studies and the associated radiopharmaceuticals.
Medicaid revenue is even more concentrated: the top three Medicaid codes account for 100.0% of Medicaid revenue, led by 78815 at $369.6K (83.1%) and A9552 at $75.4K (16.9%). There is no recorded Medicaid revenue outside these core PET-related codes, which suggests Medicaid-facing activity is narrowly focused on the same PET services tracked in Medicare.
On payer mix, Medicare is the larger payer by scale at $2.1M versus $445.1K in Medicaid, so the provider is not single-payer but clearly Medicare-dominant in dollars. Both payers are represented, however, which indicates the mobile PET/CT operation serves a mixed beneficiary population rather than exclusively Medicare or exclusively Medicaid.
The provider is a national-volume leader on several Medicare PET codes: 78815 ranks #60 of 6566 providers nationally (99th percentile; extreme outlier) and A9552 ranks #22 of 2411 providers nationally (99th percentile; extreme outlier), while A9595 ranks #20 of 528 providers nationally (96th percentile; notably above typical national volume). These rankings position the entity as a major national player for PET/CT and certain tracer administrations rather than a marginal local operator for those services.
By contrast, the provider’s Medicaid competitive standing in-state is more modest: 78815 ranks #21 of 49 providers in-state (58th percentile; typical, unremarkable volume) and A9552 ranks #17 of 33 providers in-state (50th percentile; typical, unremarkable volume). This suggests the provider’s dominance is stronger on the Medicare side nationally than on the Medicaid side within Massachusetts.
Operational nuance: the provider bills both 78815 and 78816 on Medicare (78816 accounts for $138.4K or 6.5% of Medicare revenue and ranks #148 of 1983 providers nationally, 92th percentile; typical, unremarkable volume), showing capacity to perform both whole-body and regional PET/CT protocols. The mix of A9552 (FDG) and A9595 (piflufolastat f-18) demonstrates capability to administer multiple radiopharmaceutical agents, supporting a service line that can address different diagnostic indications.
The NPI was enumerated on 2009-10-01 (~17 years ago), indicating long tenure in the market; combined with the concentrated, high-volume PET/CT billing, this longevity suggests established operational workflows and payer relationships focused on mobile PET imaging and tracer supply.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 810 | $1,320 | $1.1M |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 1,240 | $490 | $602.4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 780 | $410 | $321.3K |
| 78816 | The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The… | 110 | $1,310 | $138.4K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 910 | $410 | $369.6K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 710 | $110 | $75.4K |
How this provider's Medicaid billing volume and revenue compare to other Massachusetts providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Massachusetts median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 21 | 50 | 630 | $460 | $459.9K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | 30 | 710 | $70 | $70.5K |
Other providers in the same ZIP code as Cape Cod Pet/ct Services LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| New England Home Medical Equipment, LLC | MA | Durable Medical Equipment & Medical Supplies | $0 | $56.2M |
| Cape Medical Supply LLC | MA | Durable Medical Equipment & Medical Supplies | $0 | $15.7M |
| Urgi Center Medical Group | MA | Urgent Care Clinic/Center | $0 | $5.8M |
| Cape Cod Eye Surgery & Laser Center, LLC | MA | Ambulatory Surgical Clinic/Center | $3.5M | $238.2K |
| Cape Cod Asc LLC | MA | Ambulatory Surgical Clinic/Center | $1.4M | $25.6K |
| Town Of Sandwich | MA | Ambulance | $623.9K | $636.6K |
| Michael Oats | MA | Ophthalmology Physician | $933.3K | $0 |
| Ramon Espinosa | MA | Internal Medicine Physician | $368.2K | $0 |
| Jessica Provo | MA | Family Medicine Physician | $333.8K | $0 |
| Susan Shanley | MA | Physical Therapist | $143.8K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.